Confocal imaging and genetic testing of atypical moles and early melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational cohort will enroll about 200 atypical nevi and early melanomas scheduled for surgical excision at the University Hospital of Modena. Each lesion will undergo reflectance confocal microscopy (RCM) before removal, and excised tissue will receive next-generation sequencing (NGS) to profile genetic alterations. Researchers will correlate RCM features such as atypical cells and dermoepidermal junction disarray with molecular findings to identify patterns that distinguish early melanoma from benign nevi. No experimental treatments are given; imaging and molecular analyses are performed alongside routine clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Presence of cutaneous lesions with dermoscopic and reflectance confocal microscopy suspicion of melanocytic neoplasia, already scheduled for surgical excision
* Written informed consent obtained

Exclusion Criteria:

* Age \< 18 years
* Lesions not scheduled for excision or with uncertain dermoscopic diagnosis
* Lack of informed consent

Where it's running

• Dermatology Department, University Hospital of Modena
  Modena, Mo, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI tool helps dermatologists decide if a skin lesion could be melanoma

  A computer tool called DEXI tested with DermaGraphix Visualizer helps dermatologists see if a skin lesion might be melanoma and aims to reduce unnecessary biopsies.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · Stanford, California and 7 other locations · NCT07890415

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)

  In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07740941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.